NCT07737522Not yet recruitingPhase 2
Myocardial Metabolic Flux in Pulmonary Arterial Hypertension
Myocardial Metabolic Flux in Patients With Pulmonary Arterial Hypertension (PAH) in Response to GLP-1 Agonist Therapy: a Physiological Study Using 31-Phosphorus MR Spectroscopy
Source: ClinicalTrials.gov · Last updated 30 Jul 2026
Brief summary (registry, in English)
The rationale for this study is that GLP-1 agonist treatment is likely to influence myocardial substrate utilisation, changing the predominant source of metabolic energy within the heart to a more energetically efficient form. This is represented by a surrogate for improved mitochondrial efficiency with reduction in myocardial lactate levels (produced by inefficient myocardial glycolysis, prevalent in the ventricles of patients with pulmonary hypertension), which can be measured by 31P-magnetic resonance spectroscopy (31P-MRS).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 27 Jul 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2028
- Lead sponsor
- Imperial College London
- NCT number
- NCT07737522
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 32
- From Oct 2026 to the primary completion date, Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- • 1. Pregnancy
- 2\. Myocardial infarction within the previous 3 months
- 3\. Contraindications to MRI: Pacemakers, metallic implants, or severe claustrophobia.
- 4\. Severe renal impairment: eGFR \< 15ml/min/1.73m.
- 5\. Current use of SGLT2 inhibitors or GLP-1 agonist therapy (which significantly alter fuel substrate preference) or insulin therapy that cannot be held for the fasting scan
Who the study is looking for
- \- 1. Diagnosis of Group 1 PAH confirmed by right heart catheterisation under the National Pulmonary Hypertension Service, Royal Brompton Hospital, part of GSTT Foundation Trust 2. Age over 18, less than 85 years 3. Able to give informed consent 4. On a stable dose of PAH-specific therapies (e.g., ERA, PDE5i) for at least 3 months.
- 5\. Clinically justified prescription of GLP-1 agonist Semaglutide based on following criteria: BMI \> 30 or BMI \> 27 with at least one cardiovascular co-morbidity (systemic hypertension, diabetes, pre-diabetes, COPD, atrial fibrillation, dyslipidaemia, sleep disordered breathing)
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.